Literature DB >> 22683745

Incidence, characteristics, and outcome of left atrial tachycardias after circumferential antral ablation of atrial fibrillation.

Kristina Wasmer1, Gerold Mönnig, Alex Bittner, Dirk Dechering, Stephan Zellerhoff, Peter Milberg, Julia Köbe, Lars Eckardt.   

Abstract

BACKGROUND: Antral pulmonary vein isolation (PVI) for treatment of atrial fibrillation may induce left atrial tachycardias (ATs).
OBJECTIVE: To determine the prevalence, time course of occurrence, mechanisms, and correlation with the electrocardiogram as well as the outcome of ablation of these tachycardias. METHODS AND
RESULTS: Out of the 839 patients who underwent circumferential antral radiofrequency PVI guided by a circumferential pulmonary vein catheter at our institution between February 2005 and April 2011, 35 patients (4%) developed AT during follow-up. Six patients with left AT and a previous PVI at other institutions were also included. Of these 41 patients (26 men, 63%; age 59 ± 10 years), 26 (63%) had underlying paroxysmal atrial fibrillation and 15 (37%) had persistent atrial fibrillation. AT ablation was performed 47 ± 60 weeks after initial PVI, within the first 3 months in 16 patients (39%). The tachycardia mechanism was focal in 15 patients (37%), macroreentry in 25 patients (61%), and undetermined in 1 (2%). Focal tachycardias had an isoelectric line between distinct P waves in 13 of the 15 patients (87%), while only 4 (16%) with a macroreentrant mechanism had an isoelectric line (P <.001). Although difficult to measure, a P-wave width of >140 ms had the highest sensitivity and specificity to identify macroreentrant mechanism. Ablation was acutely successful in 32 patients (78%) and not successful in 4 (10%). In 5 patients, success could not be determined as the tachycardia terminated or degenerated during mapping. During a mean follow-up of 31 ± 17 months, 11 patients (27%; n = 9 [82%] with macroreentry) underwent repeat ablation procedure for AT. Eight patients had true recurrence, for example, the same AT, and 3 patients had a second mechanism of AT.
CONCLUSIONS: With the use of an identical ablation protocol, it was found that approximately 4% of the patients developed AT after mere circumferential antral PVI. The majority of ATs developed within a few months after ablation but occurred as late as several years after the initial PVI. Macroreentry was more frequent than a focal mechanism. Broad P waves and isoelectric lines between P waves help to distinguish a focal mechanism from a macroreentrant mechanism. Ablation has a high acute success rate, and AT recurrence occurs predominantly in macroreentrant AT.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22683745     DOI: 10.1016/j.hrthm.2012.06.007

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  21 in total

Review 1.  Myocardial Ischemia as a Genuine Cause Responsible for the Organization and "Fertilization" of Conflictogenic Atrial Fibrillation:New Conceptual Insights Into Arrhythmogenicity.

Authors:  Petras Stirbys
Journal:  J Atr Fibrillation       Date:  2013-04-06

2.  Regular atrial tachycardias following pulmonary vein isolation for paroxysmal atrial fibrillation: a retrospective comparison between the cryoballoon and conventional focal tip radiofrequency techniques.

Authors:  Justo Juliá; Gian-Battista Chierchia; Carlo de Asmundis; Giacomo Mugnai; Juan Sieira; Giuseppe Ciconte; Giacomo Di Giovanni; Giulio Conte; Giannis Baltogiannis; Yukio Saitoh; Kristel Wauters; Ghazala Irfan; Pedro Brugada
Journal:  J Interv Card Electrophysiol       Date:  2015-01-20       Impact factor: 1.900

3.  Rare and Elusive Arrhythmia: Atrial Tachycardia From Noncoronary Aortic Cusp During Catheter Ablation for Atrial Fibrillation.

Authors:  Jae-Sun Uhm
Journal:  Korean Circ J       Date:  2022-07       Impact factor: 3.101

4.  Wide area circumferential ablation for pulmonary vein isolation using radiofrequency versus laser balloon ablation.

Authors:  Jamario Skeete; Parikshit S Sharma; David Kenigsberg; Grzegorz Pietrasik; Ahmed F Osman; Venkatesh Ravi; Jeanne M Du-Fay-de-Lavallaz; Zoe Post; Jeremiah Wasserlauf; Timothy R Larsen; Kousik Krishnan; Richard Trohman; Henry D Huang
Journal:  J Arrhythm       Date:  2022-05-06

5.  Left-sided atrial tachycardia ablation in an atrial-esophageal fistula survivor.

Authors:  Sevasti-Maria Chaldoupi; Bart Maesen; Dominik Linz; Justin G L M Luermans
Journal:  HeartRhythm Case Rep       Date:  2022-03-18

Review 6.  Procedural Feasibility and Long-Term Efficacy of Catheter Ablation of Atypical Atrial Flutters in a Wide Spectrum of Heart Diseases: An Updated Clinical Overview.

Authors:  Roberto De Ponti; Raffaella Marazzi; Manola Vilotta; Fabio Angeli; Jacopo Marazzato
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

7.  Association of left atrial function with incident atypical atrial flutter after atrial fibrillation ablation.

Authors:  Esra Gucuk Ipek; Joseph E Marine; Mohammadali Habibi; Jonathan Chrispin; Joao Lima; Jack Rickard; David Spragg; Stefan L Zimmerman; Vadim Zipunnikov; Ronald Berger; Hugh Calkins; Saman Nazarian
Journal:  Heart Rhythm       Date:  2015-09-28       Impact factor: 6.343

8.  High-density versus low-density mapping in ablation of atypical atrial flutter.

Authors:  J C Balt; M N Klaver; B K Mahmoodi; V F van Dijk; M C E F Wijffels; L V A Boersma
Journal:  J Interv Card Electrophysiol       Date:  2021-01-17       Impact factor: 1.900

9.  Low-Voltage Areas as Alternative Targets for the Ablation of Unmappable Atrial Tachycardia in Patients Undergoing Atrial Fibrillation Ablation.

Authors:  Masaharu Masuda; Mitsutoshi Asai; Osamu Iida; Shin Okamoto; Takayuki Ishihara; Kiyonori Nanto; Takashi Kanda; Takuya Tsujimura; Yasuhiro Matsuda; Shota Okuno; Toshiaki Mano
Journal:  J Atr Fibrillation       Date:  2020-08-31

Review 10.  Atrial tachycardias following atrial fibrillation ablation.

Authors:  László Sághy; Cristina Tutuianu; Judith Szilágyi
Journal:  Curr Cardiol Rev       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.